Evaxion A/S (NASDAQ:EVAX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Evaxion A/S (NASDAQ:EVAX – Free Report) to a hold rating in a report published on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a research report on Tuesday, October 6th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.25.

View Our Latest Stock Report on EVAX

Evaxion A/S Price Performance

EVAX stock opened at $2.77 on Friday. Evaxion A/S has a 52 week low of $2.65 and a 52 week high of $6.92. The firm has a market capitalization of $24.99 million, a P/E ratio of -2.29 and a beta of 0.60. The company has a fifty day simple moving average of $3.12 and a two-hundred day simple moving average of $3.42. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.69.

Hedge Funds Weigh In On Evaxion A/S

Several large investors have recently modified their holdings of the stock. Rathbones Group PLC purchased a new stake in Evaxion A/S during the 1st quarter valued at $170,000. Renaissance Technologies LLC purchased a new position in Evaxion A/S during the first quarter worth $146,000. Finally, Annis Gardner Whiting Capital Advisors LLC purchased a new position in Evaxion A/S during the first quarter worth $112,000. Institutional investors own 11.04% of the company’s stock.

About Evaxion A/S

(Get Free Report)

Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to discover and develop immunotherapies and vaccines. Its research focuses on treatments for cancer and infectious diseases, with the goal of identifying targets that can prompt the immune system to recognize and attack disease. The company’s pipeline includes personalized cancer immunotherapy candidates, including EVX-01, as well as vaccine programs for cancer and infectious diseases. Evaxion uses proprietary AI platforms to analyze biological data and identify potential targets for these programs.

See Also

Analyst Recommendations for Evaxion A/S (NASDAQ:EVAX)

Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.